il-22bp
mRNA Vaccine
West China HospitalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the mRNA Vaccine cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
il-22bp mrna vaccine Xingchen Peng | Phase 1 | CC |
NeoOVIV West China Hospital | Phase 1 | CC |
Tislelizumab West China Hospital | Phase 1 | CC |
Cp-Il22Bp Mrna Intratumorally West China Hospital | Phase 1 | CC |
Same molecule, other indications
il-22bp is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →